

Andreas F Hottinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1004616/publications.pdf>

Version: 2024-02-01

31
papers

3,597
citations

687363

13
h-index

580821

25
g-index

35
all docs

35
docs citations

35
times ranked

5156
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. JAMA - Journal of the American Medical Association, 2017, 318, 2306.	7.4	1,619
2	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. JAMA - Journal of the American Medical Association, 2015, 314, 2535.	7.4	982
3	Neurologic complications of immune checkpoint inhibitors. Current Opinion in Neurology, 2016, 29, 806-812.	3.6	179
4	Performance of ¹⁸ F-FET versus ¹⁸ F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro-Oncology, 2016, 18, 426-434.	1.2	143
5	Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma. JAMA Oncology, 2018, 4, 495.	7.1	135
6	Standards of care and novel approaches in the management of glioblastoma multiforme. Chinese Journal of Cancer, 2014, 33, 32-39.	4.9	121
7	Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. Current Neurology and Neuroscience Reports, 2018, 18, 3.	4.2	83
8	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Journal of Clinical Oncology, 2022, 40, 403-426.	1.6	67
9	Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 pandemic. Neuro-Oncology, 2020, 22, 912-917.	1.2	59
10	Therapeutic Drug Monitoring of Newer Antiepileptic Drugs: A Randomized Trial for Dosage Adjustment. Annals of Neurology, 2020, 87, 22-29.	5.3	30
11	Current management of low-grade gliomas. Current Opinion in Neurology, 2016, 29, 782-788.	3.6	26
12	Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient. , 2019, 7, 336.		21
13	MEVITEM® a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation. Neuro-Oncology, 2021, 23, 1949-1960.	1.2	20
14	The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1269-1278.	0.8	20
15	Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network. Neuro-Oncology Practice, 2019, 6, 264-273.	1.6	14
16	Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial. Frontiers in Oncology, 2021, 11, 671972.	2.8	14
17	Recent developments and controversies in primary central nervous system lymphoma. Current Opinion in Oncology, 2015, 27, 496-501.	2.4	9
18	Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. Frontiers in Oncology, 2021, 11, 679702.	2.8	8

#	ARTICLE	IF	CITATIONS
19	Current Standards of Care in Glioblastoma Therapy. , 2016, , 73-80.		7
20	Metabolic and transcriptomic profiles of glioblastoma invasion revealed by comparisons between patients and corresponding orthotopic xenografts in mice. Acta Neuropathologica Communications, 2021, 9, 133.	5.2	7
21	Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer. Anticancer Research, 2016, 36, 2359-64.	1.1	7
22	A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. Swiss Medical Weekly, 2020, 150, w20256.	1.6	5
23	PET Imaging in Glioma. PET Clinics, 2013, 8, 117-128.	3.0	4
24	Multilevel severe radiculopathy from an extraneural glioblastoma cervical metastasis. , 2016, 7, 1028.		4
25	Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes. , 2020, 8, e001155.		3
26	Effect of everolimus on multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex. Respiratory Medicine Case Reports, 2020, 31, 101310.	0.4	3
27	Fitness-to-drive for glioblastoma patients. Swiss Medical Weekly, 2021, 151, w20501.	1.6	3
28	Glioma patient-reported outcome assessment in clinical care. Lancet Oncology, The, 2020, 21, e230.	10.7	2
29	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Neuro-Oncology, 2022, 24, 358-383.	1.2	1
30	Neurooncology: a Swiss army knife specialty. Current Opinion in Neurology, 2016, 29, 781.	3.6	0
31	COVID-17. TUMOR TREATING FIELDS FOR GLIOBLASTOMA THERAPY DURING THE COVID-19 PANDEMIC: EXPERT CONSENSUS ON USE AND EXPERIENCE. Neuro-Oncology, 2020, 22, ii24-ii24.	1.2	0